Artículo
Characterization of a fibroblastoid mammary carcinoma cell line (LM2) originated from a mouse adenocarcinoma
Galli, S.; Colombo, Lucas Luis
; Vanzuli, Silvia; Daroqui, Maria Cecilia
; Vidal, María del Carmen C.; Jasnis, Maria Adela; Sacerdote de Lustig, Eugenia
; Eijan, Ana Maria
Fecha de publicación:
12/2000
Editorial:
Spandidos Publications
Revista:
International Journal of Oncology
ISSN:
1019-6439
e-ISSN:
1791-2423
Idioma:
Inglés
Volumen:
17
Número:
6
Páginas:
1259-1324
Subtipo:
Artículo científico
Clasificación temática:
Resumen
We established and characterized a new mammary tumor cell line, LM2, derived from M2 mammary adenocarcinoma which spontaneously appeared in a BALB/c female mouse. The LM2 cell line has been maintained in culture for more than 40 passages and grows as poorly differentiated elongated cells. Ultrastructural and immunocytochemistry analysis revealed characteristic features of adenocarcinoma. Cytogenetic studies showed that LM2 cells are fundamentally hypotetraploid. They express metalloproteinases (MMP) and show high levels of plasminogen activator type urokinase (uPA). They were sensitive to nitric oxide (NO)-mediated cytotoxicity when NO derived from an exogenous donor. In vivo, although LM2 cells were able to grow in the lungs, they could not metastasize to the same target organ from s.c. primary tumors. The LM2 mouse mammary adenocarcinoma cell line is a suitable model to examine different aspects of tumor biology, in particular those related to the different pathways involved in the metastatic cascade and in the cytotoxicity mediated by NO.
Archivos asociados
Licencia
Identificadores
Colecciones
Recursos continuos (Eugenia Sacerdote)
Recursos continuos (Eugenia Sacerdote)
Recursos continuos (Eugenia Sacerdote)
Citación
Galli, S.; Colombo, Lucas Luis; Vanzuli, Silvia; Daroqui, Maria Cecilia; Vidal, María del Carmen C.; et al.; Characterization of a fibroblastoid mammary carcinoma cell line (LM2) originated from a mouse adenocarcinoma; Spandidos Publications; International Journal of Oncology; 17; 6; 12-2000; 1259-1324
Compartir
Altmétricas